Navigation Links
Gentris Corporation Names New Chief Scientific Advisor

MORRISVILLE, N.C., Nov. 4, 2010 /PRNewswire/ -- Gentris Corporation (, a global leader in applied clinical pharmacogenomics, announced today that Howard McLeod, Pharm.D., from The University of North Carolina at Chapel Hill (UNC) has become the Company's first Chief Scientific Advisor. Dr. McLeod, an internationally recognized expert in pharmacogenomics and personalized medicine, is the Fred N. Eshelman Distinguished Professor and Director of the Institute for Pharmacogenomics and Individualized Therapy. He holds academic appointments in the UNC Schools of Pharmacy and Medicine as well as the Lineberger Comprehensive Cancer Center.

Dr. McLeod is actively involved in global pharmacogenomics initiatives. He serves as Principal Investigator for the CREATE Pharmacogenomics Research Network and is a member of the FDA Committee on Clinical Pharmacology. He is also Vice Chairman for Pharmacogenomics with the NIH Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee. As Director of the PharmacoGenetics for Every Nation Initiative (PGENI), he works with scientists, medical experts, and government officials around the world to assist developing countries as they take advantage of pharmacogenomic innovations to improve decision-making in the use of biotechnology and pharmaceutical products.

Dr. McLeod has published more than three hundred and eighty peer-reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and serves on the editorial boards of seven scientific journals. Additionally, he sits on numerous advisory boards for industry and non-profit organizations.

Gentris Corporation, founded in 2001, is located in the heart of Research Triangle Park where it provides biotechnology and pharmaceutical companies with cutting-edge scientific guidance in patient clinical-trial selection and strategies to reduce adverse drug reactions. The Company has worked closely with sponsors to incorporate pharmacogenomics into more than five hundred clinical trials around the world. Gentris scientists design de novo genomic assays, while providing strong regulatory and clinical-implementation support. These contributions improve study accuracy and ensure that a sponsor's program is expeditiously completed. More than two hundred and fifty of Gentris' Good Laboratory Practice (GLP) compliant assays have been validated and used in clinical trials.

The Gentris Integrated BioRepository Solutions business unit provides biotechnology and pharmaceutical companies with an innovative, comprehensive system to manage study-site logistics, conduct genomic assessments, and store patient biospecimens. The Gentris Integrated BioRepository Solutions program is centralized and seamlessly connects sponsors with their global medical sites and central labs.

In his role as Chief Scientific Advisor, Dr. McLeod will provide scientific oversight for all Gentris programs while collaborating with Chief Scientific Officer Dr. Scott Clark and Vice President of Scientific Operations Suzanne Phillips to develop new research and education projects in individualized medicine that have a positive impact on global health. The first project underway is an oncology-focused, genome-wide association study (GWAS) to evaluate potential biomarkers.

Additional analyses will include multidimensional assessment of the cancer genome. Working together with other leaders in industry, academia, government, and nonprofit organizations, the Gentris Team will also be identifying new ways to evaluate genomic biomarkers and patient responses to toxicity and efficacy, which encompass a wide variety of disease areas, drug targets, mechanisms of action, and point-of-care settings.

Related Links:


"It is an exciting time for the application of genomics in drug development," said Dr. Howard McLeod, "and I am thrilled to help Gentris scientists as they establish innovative collaborations with their biotechnology and pharmaceutical partners."

"We share Dr. McLeod's vision of collaborating with leaders in academia and industry to rapidly translate new biomarker innovations into safer, more effective personalized medicines that improve global health," said Rick Williams, CEO of Gentris Corporation. "Dr. McLeod and I have both recently spent a lot of time in China. With increasing interest there, and in other emerging countries, biopharma companies have more opportunities than ever before to broaden their global pharmacogenomics studies to include ethnically diverse populations."

"We are honored that Dr. McLeod has agreed to become our Chief Scientific Advisor," said Dr. Scott Clark, Chief Scientific Officer at Gentris. "We have already identified several promising new scientific projects that combine our pharmacogenomics industry expertise with Dr. McLeod's academic experience. Our goal is to accelerate the development and validation of new biomarkers for diseases such as hepatitis and cancer."

About Gentris Corporation:

Founded in 2001, Gentris is a leading global provider of applied clinical pharmacogenomics. Gentris offers SNP genotyping, custom assay design and validation, expression analysis, and sample bio-storage, all of which are compliant with stringent GLP guidelines and are under CLIA registration. The Company is headquartered in Research Triangle Park, NC. For additional information, please visit or call 919.653.5534. Media Contact: L. Scott Clark, Ph.D. Chief Scientific Officer Gentris Corporation 919.653.5534

SOURCE Gentris Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Corporation Names New Chief Executive Officer
2. Clinical Logistics Enters Partnership with Gentris Corporation
3. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
4. DURECT Corporation Announces Third Quarter 2010 Financial Results
5. Techne Corporation Declares Dividend
6. Pharmos Corporation Reports 2010 Third Quarter Results
7. Baxa Corporation Announces 2011 Course Schedule for its STAR Center® Training Facility
8. United American Healthcare Corporation Names John M. Fife as Chairman of the Board
9. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
10. CVS Caremark Corporation to Hold Third Quarter 2010 Conference Call
11. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
Post Your Comments:
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015  Following an ... (NASDAQ: OGXI ) announced today that its Phase ... interim futility analysis of the intent-to-treat (ITT) population. In ... identified by the DMC. Both the DMC and OncoGenex ... expected in the second half of 2016, depending on ...
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Hospital Tampa is the first health care provider in the region to offer the ... is a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult ... least 40 to 45 kg, or a BMI of at least 35 to 39.9 kg ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Dr. Paul Vitenas, ... Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician Practice ... best among the many elite aesthetic physicians honored by the industry publication. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Annual 2015 Golden Bridge Business Awards under the New Products and Services category ... web based sample management software that helps labs organize data and ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been awarded a fixed price per sprint agile development contract to support ... $34 million over five years, provides software engineering, infrastructure, as well as operations ...
Breaking Medicine News(10 mins):